Time to PSA progression was 3.16 months ( 95 % confidence interval ( CI ) : 1.09 , not reached ( NR ) ) for Arm A and 3.09 months ( 95 % CI : 1.22 , NR ) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B ( 42 vs. 5 % ; p = 0.019 ) .